Navigation Links
Novum to Open State-of-the-Art Clinical Research Facility in Houston, TX
Date:4/5/2013

HOUSTON, April 5, 2013 /PRNewswire/ -- Novum Pharmaceutical Research Services, a leading contract research organization (CRO) serving the pharmaceutical industry in Phase I-Phase IV clinical trials and related services, announced today the opening of a new early-stage clinical facility in Houston, TX. The 55,000 square foot facility is scheduled to be operational in August, 2013.

"This exciting new facility reflects Novum's continued growth and our deep commitment to our clients' needs," said Christopher H. Chamberlain , Novum's Chief Executive Officer. "Like our other research facilities, it will provide a safe, convenient, and pleasant environment for our study participants," he added.

The GCP-compliant facility is being custom-built in Houston's Westchase district, a short distance from Novum's current clinics. The new facility will have seven research units that are designed to make the most efficient use of its 225 beds. Additionally, a 12-bed intensive monitoring unit will allow for early phase research studies requiring continuous cardiac and other specialized safety monitoring.  The floor plan and layout will provide a high degree of flexibility in space planning to handle multiple types of study designs. 

"While our employees and study participants truly make the difference at Novum, bringing this state-of-the-art facility online will raise the bar for Novum and the industry," said Dr. Darin Brimhall , Novum's Vice President of Clinic Operations.

About Novum PRS
Novum is a contract research organization ("CRO") that provides Phase I through IV clinical research, data management, statistical and reporting services to the pharmaceutical and related industries. Founded in 1972, it operates Phase I research facilities with a total of 550 beds in three USA'/>"/>

SOURCE Novum Pharmaceutical Research Services
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. NorDx Enhances Clinical Laboratory Diagnostic Services with State-of-the-Art Technology
2. Alma Lasers to Showcase State-of-the-Art Innovations for Aesthetic Treatment at AAD
3. Salix Pharmaceuticals Donates $500,000 To ASGEs IT&T Capital Campaign To Build A New State-of-the-Art GI Training Center
4. University Hospitals and Philips Healthcare to Showcase State-of-the-art Imaging Technology at Cleveland Medical Mart
5. ImmusanT Relocates Offices to State-of-the-Art Innovation Facility
6. Forum Extended Care Services Announces Plans to Move to Larger, State-Of-the-art Facility
7. Specialty Silicone Fabricators Inaugurates New State-of-the-Art Facility in Paso Robles
8. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
9. For Osteoporosis and Osteopenia, Clinical Data and Thought Leaders Opinions Indicate that AMG-785/CDP-7851 and Odanacatib Have Advantages Over Alendronate
10. Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop
11. VG Life Sciences Reports Positive Safety Results from Second Cohort Enrollment in Solid Tumor Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 30, 2015  Astellas today announced topline results ... efficacy and safety of intravenous (IV) and oral ... development for adults with candidemia and other invasive ... demonstrated that the trial did not meet its ... in isavuconazole-treated patients at the end of IV ...
(Date:7/29/2015)... July 29, 2015 Insulet Corporation (NASDAQ: PODD ... its OmniPod ® Insulin Management System, today announced ... 30, 2015. The Company also announced that it will ... results and conference call from Thursday, July 30, as ... Revenue Highlights: , Preliminary second ...
(Date:7/29/2015)...  UBM Canon brings MEDevice San Diego Conference & ... on September 1-2, 2015, with a multi-track conference program ... Business Development track will be a panel on How ... featuring Renee Ryan , Vice President of Venture ... , Partner, Canaan Partners; and Jordan Kramer , ...
Breaking Medicine Technology:Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5Insulet Reports Preliminary Second Quarter 2015 Revenue Results 2Insulet Reports Preliminary Second Quarter 2015 Revenue Results 3Insulet Reports Preliminary Second Quarter 2015 Revenue Results 4Insulet Reports Preliminary Second Quarter 2015 Revenue Results 5MEDevice San Diego Offers Tips on Securing Financial Backing from Investors 2
... PXS; Nasdaq: PXSL) today announced that the company ... reached agreement on the phase 3,registration trial of ... The SPA process allows for FDA evaluation ... primary basis of an efficacy claim in support ...
... 19 The Australian company Fermiscan,who is using ... new breast cancer,screening test through the analysis of ... 69% in detecting breast cancer., (Photo: ... the Journal of the American Medical,Association(1) (US study), ...
Cached Medicine Technology:Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 2Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 3New Australian Technology: Detecting Breast Cancer With Hair 2New Australian Technology: Detecting Breast Cancer With Hair 3New Australian Technology: Detecting Breast Cancer With Hair 4
(Date:7/30/2015)... ... ... Bird B Gone, the leader in bird control products for commercial, industrial ... birds from the AC units and ventilation systems on hospital roofs. Bird droppings can ... Nile virus. When these droppings dry, the fine powder can be carried into hospitals ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... at multinational organizations and NGO’s, according to a new survey by leading international ... that property damage and employee medical expenses represented the largest sources of financial ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... After a ... Argus II retinal implant, more commonly known as the “bionic eye,” researchers have determined ... safe and viable tool for patients facing or already affected by complete vision loss ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... are living longer and do not find a complete removable denture acceptable. The ... of care. The practices that incorporate less expensive, immediate loading techniques will have ...
(Date:7/30/2015)... Orem, UT (PRWEB) , ... July 30, 2015 , ... When trying to gain weight, many people place a lot ... the amount of calories that need to be consumed. However, another key component to successful ... to gain weight. To assist with this, CB-1 Weight Gainer gives three tips on ...
Breaking Medicine News(10 mins):Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 3Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 2Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 3
... April 18 An ex-White house aide,Robert Weiner, and ... cancer lab, are reporting that many scientists believe that ... a drop in real dollars for,cancer research, and private ... of the federal government." Discoveries are being,lost due to ...
... Coyote goes,hungry in cartoon land, it,s because Roadrunner ... Food Bank wins when nobody goes hungry., ... ), In that spirit, strategic communications firm ... to highlight the tragedy of hunger in New,Mexico ...
... showing the cancer may have an Achilles, heel, report suggests ... Gleevec has forced metastatic melanoma into remission for the first ... , The case involves a 79-year-old woman with melanoma tumors ... an abnormality in a gene called KIT, so the patient ...
... Family Research Council,Action applauds GOP Presidential candidate ... Villanova University supporting the pro-life,platform of the Republican ... of possible running mates., FRC Action,s Senior ... hear Senator McCain depict his support for life ...
... TSTF ), a national provider of healthcare and administrative,staffing ... of Shareholders held on April 17, 2008, at the ... annual meeting, shareholders approved the election of Rick J.,Filippelli ... Directors. In,addition, the Company,s shareholders also approved a proposal ...
... drugs had sharper declines in thinking skills, study finds ... known as anticholinergic drugs -- used to treat ulcers, ... -- may cause older people to lose their thinking ... medicines, new research suggests. , "What we found is ...
Cached Medicine News:Health News:Reduced Funds for Cancer is Cost of Iraq, Say Ex-White House Aide, Cancer Researchers 2Health News:BEEP BEEP!! Strategic Communications Firm DW Turner Thwarts Hunger in Partnership With Roadrunner Food Bank 2Health News:Gleevec Pushes Advanced Melanoma Into Remission 2Health News:FRC Action Praises John McCain's Pro-Life Comments 2Health News:TeamStaff, Inc. Announces Results From Annual Meeting of Shareholders 2Health News:TeamStaff, Inc. Announces Results From Annual Meeting of Shareholders 3Health News:Common Medications May Harm Memory in Older People 2Health News:Common Medications May Harm Memory in Older People 3
... of any biological activity but appears to ... of insulin. Although insulin and C-Peptide are ... fasting levels of C-Peptide are 5-10 fold ... the longer half-life of C-Peptide. The glucagon ...
... The Array Multifocal IOL was designed ... with independence from glasses in most situations. ... IOL is similar to that of a ... usually much better and about 19 in ...
Inquire...
... IgG Enzymelinked Immunosorbent Assays(ELISA) is intended for ... antibody to Measles Rubeola) virus in human ... for the determination of immune status. Paired ... demonstrate seroconversion or a significant rise in ...
Medicine Products: